Clinical Trials Logo

Clinical Trial Summary

The objective of this study is to establish the performance of an assay that detects mRNA transcript levels in patients diagnosed with CML. The study is conducted at locations within the United States. Testing is performed on peripheral blood specimens provided by eligible enrolled patients. Results from this study will not be used for patient management decisions.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03421626
Study type Observational
Source Cepheid
Contact
Status Completed
Phase
Start date November 8, 2017
Completion date August 20, 2018

See also
  Status Clinical Trial Phase
Completed NCT05640804 - A Bioequivalence Study of Dasatinib Tablet Phase 1
Completed NCT01720264 - Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant Phase 2
Completed NCT00241358 - Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies Phase 1/Phase 2
Completed NCT00862719 - Sitagliptin Umbilical Cord Blood Transplant Study Phase 2
Recruiting NCT00619879 - Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Phase 3
Completed NCT00129740 - Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) Phase 2
Completed NCT02117115 - Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Phase 0
Terminated NCT00569179 - A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies Phase 1